Belgium's IBA signs three deals in Asia
BRUSSELS, Oct 11 (Reuters) - Belgian cancer diagnosis and therapy company IBA has signed three deals in Asia worth a total of 10 million euros ($12.90 million) for the sale of specialised...
View ArticleREFILE-Antidepressants linked to risk of brain bleeds: study
(Adds reporter's name at bottom) Oct 18 (Reuters) - People using a common class of antidepressants may have slightly increased odds of suffering bleeding in the brain - though the risk is still very...
View ArticleExperts to Examine the Clinical Impact of Recent FDA Decisions and...
BOSTON, Oct. 12, 2012 /PRNewswire via COMTEX/ -- The approval of two new weight-loss medications, cutting-edge data on novel hypertension therapies and the approval of a novel prescription omega-3...
View ArticleIndonesia acts to over-ride patents on HIV drugs
JAKARTA (Reuters) - Indonesia's government has taken steps to over-ride patents for HIV drugs, following the lead of other Asian states that have allowed the production of cheap generic drugs that cut...
View ArticleAntidepressant use associated with increased mortality among critically ill...
The researchers conducted a retrospective study using the electronic medical records of 10,568 patients to look at in-hospital mortality and mortality a year after being admitted to the ICU. "We found...
View ArticleResearch and Markets: Psoriasis - Thought Leader Panel 2012 - A Summary of...
DUBLIN, Oct 11, 2012 (BUSINESS WIRE) -- Research and Markets ( ) has announced the addition of the "Psoriasis Thought Leader Panel #22 2012-04" report to their offering. Psoriasis Thought Leader Panel...
View ArticleAstraZeneca and Targacept Announce Remaining TC-5214 Phase 3 Efficacy...
LONDON & WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- AstraZeneca and Targacept, Inc. (TRGT) today announced top-line results from the remaining Phase 3 studies investigating efficacy, tolerability and...
View ArticleResearch and Markets: The Top 60 European Manufacturers Of Generic...
DUBLIN, Oct 12, 2012 (BUSINESS WIRE) -- Research and Markets ( ) has announced the addition of the "The Top 60 European Manufacturers Of Generic Pharmaceuticals" report to their offering. "The Top 60...
View ArticleResearch and Markets: Multiple Sclerosis - Thought Leader Panel -...
DUBLIN, Oct 11, 2012 (BUSINESS WIRE) -- Research and Markets ( ) has announced the addition of the "Multiple Sclerosis Thought Leader Panel #15 Pharmacoeconomics" report to their offering. Multiple...
View ArticleCEO Roundtable on Cancer Clinical Trial Data Sharing Encourages Innovation &...
CARY, N.C., Oct 11, 2012 (BUSINESS WIRE) -- The CEO Roundtable on Cancer's Life Sciences Consortium has initiated Project Data Sphere, a collaborative effort to create a shared platform where clinical...
View ArticleResearch and Markets: Diabetes: Clinican's Desk Reference
DUBLIN, Oct 11, 2012 (BUSINESS WIRE) -- Research and Markets ( ) has announced the addition of the "Diabetes: Clinican's Desk Reference" book to their offering. A Clear, Concise And Handy Resource For...
View ArticleAntidepressants linked to risk of brain bleeds
NEW YORK (Reuters Health) - People using a common class of antidepressants may have slightly increased odds of suffering bleeding in the brain - though the risk is still very small, researchers...
View ArticlePeri-op antidepressant use safe for face-lift surgery
Sanaz Harirchian, M.D., from the University of Medicine and Dentistry of New Jersey in Newark, and colleagues assessed the rate of post-face-lift hematoma among SSRI users and...
View ArticleResearch and Markets: DRG Insights: Multiple Sclerosis (G7) - Novel...
DUBLIN, Oct 11, 2012 (BUSINESS WIRE) -- Research and Markets ( ) has announced the addition of Decision Resources, Inc's new report "DRG Insights: Multiple Sclerosis (G7)" to their offering. DRG...
View ArticleAcademy of Managed Care Pharmacy Announces 2011 Journal of Managed Care...
Honorable Mention Goes to Researchers from WellPoint and..."/> Download image...
View ArticleSecond Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In...
THE WOODLANDS, Texas, Oct. 12, 2012 /PRNewswire via COMTEX/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human...
View ArticleLexicon Initiates Phase 3 Clinical Trial Of Telotristat Etiprate In Patients...
THE WOODLANDS, Texas, Oct. 12, 2012 /PRNewswire via COMTEX/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments...
View ArticleMore Than a Third of Newly Diagnosed Major Depressive Disorder Patients Who...
Treatment Algorithms Analysis for Major Depressive Disorder Now Available from BioTrends Research Group EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and...
View ArticleSignificant Opportunity Remains in the Unipolar Depression Market Due to the...
Through 2015, Sales of Atypical Antipsychotics for Treatment of Unipolar Depression Will Reach More than $2.5 Billion, According to Findings from Decision Resources BURLINGTON, Mass.--(BUSINESS...
View ArticleResearch and Markets: Antidepressants Market to 2018 - Despite Safety...
DUBLIN, Oct 23, 2012 (BUSINESS WIRE) -- Research and Markets ( ) has announced the addition of the "Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors...
View ArticleEuthymics Completes Enrollment in TRIADE, Its Advanced Trial of Amitifadine...
CAMBRIDGE, Mass., Oct 11, 2012 (BUSINESS WIRE) -- ----Trial Further Evaluates Amitifadine, Euthymics' Proprietary Serotonin-Preferring Triple-- Euthymics Bioscience, Inc. today announced completion of...
View ArticleResearch and Markets: Key Findings from Treatment Algorithms: Generalized...
DUBLIN, Oct 12, 2012 (BUSINESS WIRE) -- Research and Markets ( ) has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Generalized Anxiety...
View ArticleResearch and Markets: 2012 Key Findings from Treatment Algorithms: Major...
DUBLIN, Oct 11, 2012 (BUSINESS WIRE) -- Research and Markets ( ) has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Major Depressive Disorder"...
View ArticlePfizer Announces Top-Line Efficacy Results From A Phase 4 Study Of PRISTIQ®...
New Data Add to Evidence Supporting PRISTIQ as a Treatment Option for MDD Pfizer Inc. (NYSE: PFE) announced today that a Phase 4 study evaluating the efficacy of PRISTIQ® (desvenlafaxine) Extended...
View ArticlePfizer Announces Top-Line Efficacy Results From A Phase 4 Study Of PRISTIQ®...
New Data Add to Evidence Supporting PRISTIQ as a Treatment Option for MDD NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 4 study evaluating the efficacy of PRISTIQ®...
View ArticleNew Research Presented at CPNP Finds Lower Cost of Care, Higher Adherence...
COVINGTON, La.--(BUSINESS WIRE)--Overall medical costs are lower and patients are more adherent to therapy for Major Depressive Disorder (MDD) if adjunctive L-methylfolate is used to complement...
View ArticleForest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of...
(Source: Forest Laboratories Inc) NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories announced today that FETZIMA™ (levomilnacipran...
View ArticleForest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of...
NEW YORK & CASTRES, France--(BUSINESS WIRE)-- Forest Laboratories, Inc. (FRX) and Pierre Fabre Laboratories announced today that FETZIMA" (levomilnacipran extended-release capsules), a once-daily...
View ArticleADDING MULTIMEDIA: Forest Laboratories and Pierre Fabre Laboratories...
(Source: Forest Laboratories Inc) NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories announced today that FETZIMA™ (levomilnacipran...
View ArticleAmong New Agents Entering the Unipolar Depression Market Over the Next...
Through 2022, New Drug Launches Will Not Offset Market Decline Caused By Expanding Generic Competition Among Antidepressants and Antipsychotics, According to a New Report from Decision Resources...
View ArticleRottenstein Law Group Reports on New Antidepressant Research Suggesting Link...
The Rottenstein Law Group, which represents clients with claims stemming from injuries allegedly caused by Zoloft, has learned of new research suggesting a link between critically ill patients' Zoloft...
View ArticleMidwest Eating Disorders Conference Focuses on Wellness, Not Weight...
CHICAGO, Oct. 11, 2012 /PRNewswire via COMTEX/ -- Timberline Knolls Residential Treatment Center today announced it is sponsoring the upcoming 2012 Annual Midwest Eating Disorders Conference, put on...
View ArticleLamotrigine is One of the Most Commonly Prescribed Drugs Among Newly...
Quetiapine Products Capture Class-Leading Patient Shares Among Recently Treated Patients, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 23, 2013 /PRNewswire/ -- Decision...
View ArticleClose To 50 Percent Of Drug-Treated Major Depressive Disorder Patients...
Among Recently Treated Patients, Abilify Is the Leading Atypical Antipsychotic, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 26, 2013 /PRNewswire/ -- Decision Resources,...
View ArticleForest Announces New FETZIMA™ (levomilnacipran ER capsules) Now Available in...
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) announced today that FETZIMA™ (levomilnacipran ER capsules), is now available in pharmacies throughout the United States. FETZIMA was...
View ArticleAccounting for Nearly 90 Percent of Major-Market Sales in 2011, the United...
The Uptake of Latuda and the Launch of Cariprazine Will Help Temper the Decline in Sales of the Atypical Antipsychotics Drug Class, According to Findings from Decision Resources BURLINGTON,...
View ArticleForest Laboratories, Inc. to Present Data about Levomilnacipran and...
(Source: Forest Laboratories Inc) NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data from its Major Depressive Disorder (MDD) portfolio,...
View ArticleForest Laboratories, Inc. to Present Data about Levomilnacipran and...
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data from its Major Depressive Disorder (MDD) portfolio, levomilnacipran and vilazodone, at the...
View ArticleForest Laboratories, Inc. to Present Data about Levomilnacipran and...
Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data from its Major Depressive Disorder (MDD) portfolio, levomilnacipran and vilazodone, at the American Psychiatric...
View ArticleSurveyed U.S. Psychiatrists Would Prescribe Otsuka/Lundbeck's Brexpiprazole...
Decision Resources Group Logo. (PRNewsFoto/Decision Resources Group) × Decision Resources Group Logo. (PRNewsFoto/Decision Resources Group) BURLINGTON, Mass., June 23, 2014 /PRNewswire/ -- Decision...
View ArticlePharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis...
NEW YORK, June 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: PharmaPoint: Major Depressive Disorder - US Drug Forecast and...
View ArticlePharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market...
, June 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market...
View ArticleResearch and Markets: PharmaPoint: Major Depressive Disorder - 5EU Drug...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8k5fxv/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - 5EU Drug...
View Article
